Jiang Hua, Zhao Shanchao, Li Ganhong
Department of Urology, The Fifth Affiliated Hospital of Zunyi Medical University, Zhuhai.
Department of Urology, Nanfang Hospital, Southern Medical University/The First School of Clinical Medicine, Southern Medical University, Guangzhou.
Medicine (Baltimore). 2020 Nov 20;99(47):e23263. doi: 10.1097/MD.0000000000023263.
Double primary clear cell carcinomas of the liver (PCCCL) and kidney are extremely rare; moreover, there have been no reported cases of adrenal metastasis from primary clear cell tumors of the liver.
A 47-year-old male patient was admitted to our clinic with space-occupying lesions in the left kidney and liver during a regular medical examination.
The tumors in the kidney and liver were diagnosed as primary clear cell carcinoma by histopathological examination.
The patient subsequently underwent nephron-sparing surgery of the left kidney and radical partial excision of the right liver lobe by laparoscopic surgery. Transcatheter arterial chemoembolization (TACE) was performed for the patient 2 weeks after tumor resection. One month after the operation, the patient started adjuvant therapy with sorafenib (400 mg twice per day orally). However, follow-up CT imaging revealed a solid mass measuring 1.9 × 2.0 × 2.0 cm in the right adrenal gland at 2 months postoperatively, and then the patient underwent radiofrequency ablation (RFA) for the right adrenal tumor.
The patient remained cancer free for 2 years following the diagnosis despite early right adrenal metastasis.
Hepatocyte immunostaining is sufficient for the diagnosis of PCCCL.
肝脏和肾脏的双原发性透明细胞癌(PCCCL)极为罕见;此外,尚无原发性肝脏透明细胞瘤发生肾上腺转移的病例报道。
一名47岁男性患者在定期体检时因左肾和肝脏占位性病变入住我院。
肾脏和肝脏的肿瘤经组织病理学检查诊断为原发性透明细胞癌。
患者随后接受了左肾保留肾单位手术及腹腔镜下右肝叶根治性部分切除术。肿瘤切除术后2周对患者进行了经动脉化疗栓塞术(TACE)。术后1个月,患者开始口服索拉非尼(400mg,每日2次)进行辅助治疗。然而,术后2个月的随访CT影像显示右肾上腺有一个大小为1.9×2.0×2.0cm的实性肿块,随后患者接受了右肾上腺肿瘤的射频消融术(RFA)。
尽管早期出现右肾上腺转移,但诊断后患者2年无癌。
肝细胞免疫染色足以诊断PCCCL。